Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Radiopharmaceuticals

Volume 4 Issue 4
ISSN: 1874-4710
eISSN: 1874-4729

 

   All Titles

  Targeted Alpha Therapy with 213Bi
  pp.295-305 (11) Authors: Alfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
doi: 10.2174/1874471011104040295
 
 
      Abstract

The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.

 
  Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, preclinical studies, clinical application, Alpha emitting radionuclides, RADIONUCLIDE GENERATORS, radiolabeled peptide, SPECT
  Affiliation: European Commission, Joint Research Centre, Institute for Transuranium Elements, PO Box 2340, 76125 Karlsruhe, Germany.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers